Author

G. Matusali

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Organism:mouse· 3 Assay:proteomics· 3 Research Focus:benchmarking· 1 Approach:deep learning· 1

Frequent Co-Authors

F. Colavita· 3 shared D. Lapa· 2 shared A. Caruso· 1 shared A. Challis· 1 shared A. Conforti· 1 shared A. Folgori· 1 shared A. Lahm· 1 shared A. Leuzzi· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

F. Colavita

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Characterization of raloxifene as potential pharmacological agent against SARS-CoV-2 and its variants

D. Iaconis, C. Talarico, C. Manelfi, M. C. Cesta, M. Zippoli, F. Caccuri, G. Matusali, L. Bordi, L. Scorzolini, E. M. Bucci, A. Caruso, E. Nicastri, M. Allegretti, A. R. Beccari

This paper identifies raloxifene as a potential drug candidate for treating COVID-19 through virtual screening and pharmacological characterization across multiple viral variants.

bioRxiv · Oct 22, 2021Pharmacology & Toxicology

COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

A. Conforti, E. Marra, F. Palombo, G. Roscilli, M. Rava, V. Fumagalli, A. Muzi, M. Maffei, L. Luberto, L. Lione, E. Salvatori, M. Compagnone, E. Pinto, E. Pavoni, F. Bucci, , De F

This paper evaluates a DNA vaccine candidate, COVID-eVax, which induces strong neutralizing antibodies and T cell responses against SARS-CoV-2 in animal models, showing protective effects against viral challenge.

bioRxiv · Jun 14, 2021 · PreprintImmunology

Potential for virus endogenization in humans through testicular germ cell infection: the case of HIV

D. Mahe, G. Matusali, C. Deleage, R. Alvarenga, A.-P. Satie, A. Paggliuzza, R. Mathieu, S. Lavoue, B. Jegou, L. de Franca, N. Chomont, L. Houzet, A. Rolland, N. Dejucq-Rainsford

This study investigates whether HIV can integrate into human testicular germ cells, suggesting potential for endogenization.

Journal of Virology · Nov 23, 2020Peer-reviewedMicrobiology

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

A. Vitelli, S. Capone, A. Raggioli, M. Gentile, S. Battella, A. Lahm, A. Sommella, A. M. Contino, R. A. Urbanowicz, R. Scala, F. Barra, A. Leuzzi, E. Lilli, G. Miselli, A. Noto, , S. Colloca

This paper evaluates a gorilla adenovirus vaccine candidate for COVID-19, showing it is immunogenic in mice and macaques and supports its advancement to a Phase I clinical trial.

bioRxiv · Oct 22, 2020Immunology

Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells

S. Miersch, M. Ustav, Z. Li, J. B. Case, S. Ganaie, G. Matusali, F. Colavita, D. Lapa, M. R. Capobianchi, G. Novelli, J. B. Gupta, S. Jain, P. P. Pandolfi, M. S. Diamond, G. Amarasinghe, , S. S. Sidhu

The paper describes synthetic monoclonal antibodies that neutralize SARS-CoV-2 by binding to the spike protein and blocking ACE2 receptor interaction, showing potent antiviral activity.

bioRxiv · Jun 5, 2020 · PreprintBiochemistry